 price
thesi updat report mix in-line organ
revenu growth ep beat driven lower tax revenue
front new product seem show momentum highlight
pharma flat continu remain challeng
guid within rang expect mid point
st ep guid point margin degrad
current multipl level remain elev rel growth
profil key question bull whether guid
conserv management seem made conserv
 industri cautiou spend interest see ceo chri
oconnel note china grew dd last year
year challeng rev
assum flat growth impli bp also
assum stabl small molecul end market also seem
conserv us hand increas sg spend rais
question whether invest commerci
infrastructur get readi new product contribut bear
doubt point continu declin instrument sign
still lose share given invest step
lower ep estim lower pt
equat ep multipl in-line recent trade level
pleas see guid color market color
pleas see analyst certif import disclosur page report evercor isi affili seek busi
compani cover research report investor awar firm may conflict interest could affect object
report investor consid report singl factor make invest decis
core growth assum pt new product contribut
ep
modest dilut andrew allianc
extra sell day vs
ep
fx less hw current rate
small molecul modestli see pent demand
believ market share remain stabl turn market condit
 led new product intro
industri
china
outlook cautiou steadi pharma industri moder food stabil
corona viru impact embed guid
america
us flat strength larg molecul food biomed research off-set weak small molecul materi
europ solid demand mass spec
outlook stabil brexit work out
repod mm share mm
expect lc market stabl ta return growth recur stabl
 spend tick
gm declin driven fx rate lower fix cost absorpt mix
lower tax rate due profit mix tax jurisdict
sold bioaccord system combin
andrew allianc drive instrument
valuat methodolog base mix discount cash flow analysi rel valuat multipl
risk valuat includ regulatori risk overal market risk well unforeseen event relat individu cover
compani broader sector includ new competit product technolog
articl articl
time dissemin februari
analyst luke sergott vijay kumar primarili respons prepar research report attest follow view
opinion render research report reflect person view subject compani issuer part
research analyst compens directli relat specif recommend view research report
